Travere Therapeutics (TVTX) Stock Forecast & Price Target

$18.37 -0.10 (-0.54%)

As of 01/17/2025 04:00 PM Eastern

Travere Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
1

Buy
12

Based on 13 Wall Street analysts who have issued ratings for Travere Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a hold rating, and 12 have given a buy rating for TVTX.

Consensus Price Target

$24.00
30.65% Upside

According to the 13 analysts' twelve-month price targets for Travere Therapeutics, the average price target is $24.00. The highest price target for TVTX is $41.00, while the lowest price target for TVTX is $19.00. The average price target represents a forecasted upside of 30.65% from the current price of $18.37.

Get the Latest News and Ratings for TVTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors.

TVTX Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)	10 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$24.00	$23.67	$21.38	$17.92
Forecasted Upside	30.65% Upside	37.76% Upside	19.00% Upside	105.07% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

TVTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TVTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Travere Therapeutics Stock vs. The Competition

Type	Travere Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.65% Upside	24,741.15% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent TVTX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/15/2025	HC Wainwright 2 of 5 stars	Ed Arce Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$18.00 ➝ $22.00	+28.88%
1/10/2025	Cantor Fitzgerald 4 of 5 stars	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
11/14/2024	Piper Sandler 2 of 5 stars		Boost Target	Neutral ➝ Neutral	$12.00 ➝ $22.00	+19.70%
11/1/2024	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $27.00	+51.26%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$18.00 ➝ $20.00	+7.76%
10/21/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Bansal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$9.00 ➝ $27.00	+51.09%
10/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$18.00 ➝ $20.00	+15.54%
10/9/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$23.00 ➝ $41.00	+140.19%
10/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$17.00 ➝ $25.00	+50.06%
10/8/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+31.06%
Get the Latest News and Ratings for TVTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/30/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$23.00 ➝ $22.00	+58.50%
9/27/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Nochomovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$23.00 ➝ $19.00	+32.13%
9/13/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$20.00 ➝ $23.00	+72.16%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$8.00 ➝ $10.00	+17.10%
9/22/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$30.00 ➝ $14.00	+89.19%
9/21/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/22/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$30.00	+82.37%
5/5/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:26 PM ET.

TVTX Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Travere Therapeutics is $24.00, with a high forecast of $41.00 and a low forecast of $19.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There is currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares.
: According to analysts, Travere Therapeutics's stock has a predicted upside of 30.65% based on their 12-month stock forecasts.
: Travere Therapeutics has been rated by research analysts at Barclays, Cantor Fitzgerald, HC Wainwright, Piper Sandler, and Scotiabank in the past 90 days.
: Analysts like Travere Therapeutics more than other "medical" companies. The consensus rating score for Travere Therapeutics is 2.92 while the average consensus rating score for "medical" companies is 2.82. Learn more on how TVTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:TVTX) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Travere Therapeutics (TVTX) Stock Forecast & Price Target